What Is Outlook 2019?
A New Year and a new look. For 2019 we have merged the Scrip 100 with In Vivo’s annual preview magazine, creating a new beast known as Outlook. This encompasses all the best aspects of both issues and covers more topic areas than ever before.
You may also be interested in...
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
In the latest instalment of our VC playbook series, In Vivo sits down with Roel Bulthuis, managing partner at INKEF Capital, to discuss the group’s approach to health care investing in Europe, the importance of funding a team not just a project and how life sciences venture capital is evolving with the emergence of health tech.
Our readers have been voting and the results have been counted. The winners of In Vivo's annual Deals Of The Year contest are ...